Literature DB >> 9693956

SHP-2, SH2-containing protein tyrosine phosphatase-2.

M Stein-Gerlach1, C Wallasch, A Ullrich.   

Abstract

SHP-2 is an ubiquitously expressed cytosolic protein tyrosine phosphatase composed of two amino-terminal SH2 domains, a central phosphatase domain and a carboxy-terminal tail. Upon activation of cells with different stimuli, SHP-2 is recruited to the plasma membrane where it can associate with a number of tyrosine phosphorylated molecules, including receptor tyrosine kinases (e.g. growth factor receptors), multisite adapter proteins and cell adhesion molecules. SHP-2 is thought to function as a positive mediator of signals generated by activated membrane receptor complexes although the number and diversity of binding partners and substrates identified thus far suggests that it may have other functions. It is likely that several negative regulatory influences exist but that these are obscured by its positive function making the investigation of the inhibitory effects of this phosphatase difficult. The positive regulatory role of SHP-2 in signal cascades leading to cell growth suggests involvement in tumorigenesis, raising the possibility that SHP-2 may be a target in the treatment of some forms of cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9693956     DOI: 10.1016/s1357-2725(98)00002-8

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  15 in total

1.  The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase.

Authors:  C R Maroun; M A Naujokas; M Holgado-Madruga; A J Wong; M Park
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation.

Authors:  Geraldine Ferjoux; Frederic Lopez; Jean-Pierre Esteve; Audrey Ferrand; Eric Vivier; Frederic Vely; Nathalie Saint-Laurent; Lucien Pradayrol; Louis Buscail; Christiane Susini
Journal:  Mol Biol Cell       Date:  2003-07-11       Impact factor: 4.138

3.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Authors:  Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2002-05-01       Impact factor: 11.025

4.  Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.

Authors:  Gunamani Sithanandam; George T Smith; Janet R Fields; Laura W Fornwald; Lucy M Anderson
Journal:  Am J Respir Cell Mol Biol       Date:  2005-07-29       Impact factor: 6.914

5.  The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.

Authors:  Michelle A Edwards; Kathryn Crombie; Christine Schramm; Maike Krenz
Journal:  J Appl Physiol (1985)       Date:  2014-10-30

Review 6.  An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies.

Authors:  Jae-Sung Yi; Sravan Perla; Anton M Bennett
Journal:  Cardiovasc Drugs Ther       Date:  2022-02-14       Impact factor: 3.727

Review 7.  A comprehensive review of SHP2 and its role in cancer.

Authors:  Moges Dessale Asmamaw; Xiao-Jing Shi; Li-Rong Zhang; Hong-Min Liu
Journal:  Cell Oncol (Dordr)       Date:  2022-09-06       Impact factor: 7.051

8.  Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.

Authors:  Maike Krenz; James Gulick; Hanna E Osinska; Melissa C Colbert; Jeffery D Molkentin; Jeffrey Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

9.  Cross-talk between ICAM-1 and granulocyte-macrophage colony-stimulating factor receptor signaling modulates eosinophil survival and activation.

Authors:  Konrad Pazdrak; Travis W Young; Susan Stafford; Barbara Olszewska-Pazdrak; Christof Straub; Vitaliy Starosta; Allan Brasier; Alexander Kurosky
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

10.  A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.

Authors:  Raphael Carapito; Nicodème Paul; Meiggie Untrau; Louise Ott; Nadège Corradini; Sylvaine Poignant; Loïc Geffroy; Emmanuelle Caldagues; Marie-Françoise Heymann; Elisabeth Cassagnau; Bertrand Isidor; Seiamak Bahram
Journal:  J Hum Genet       Date:  2013-11-14       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.